Xichun Hu, MD, PhD
Fudan University
14
14
7
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (14)
Showing 10 of 14 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Alice P Chen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Puma
Biotechnology
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
min yan
Henan Cancer Hospital
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (14)
Showing 14 of 14 trials
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
Fulvestrant 500mg in Patients With Advanced Breast Cancer
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
All 14 trials loaded